{"ModuleTitle": "Company Description", "CompanyName": "Regulus Therapeutics Inc.", "Symbol": "RGLS", "Address": "10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO, California, 92121, United States of America", "Phone": "858-202-6300", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a clinical-stage biopharmaceutical company focused on discovering and\r\ndeveloping first-in-class drugs targeting microRNAs to treat diseases with\r\nsignificant unmet medical need. We were formed in 2007 when Alnylam\r\nPharmaceuticals, Inc. (\"Alnylam\") and Ionis Pharmaceuticals, Inc. (\"Ionis\")\r\ncontributed significant intellectual property, know-how and financial and human\r\ncapital to pursue the development of drugs targeting microRNAs pursuant to a\r\nlicense and collaboration agreement. Our most advanced product candidates are\r\nRG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of\r\nAlport syndrome, a life-threatening kidney disease with no approved therapy\r\navailable. In November 2018, we and Sanofi agreed to transition further\r\ndevelopment activities of our miR-21 programs, including our RG-012 program, to\r\nSanofi.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f12%2f0001628280-20-003483.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Crispina Calsada", "title": "Chief Financial Officer"}, {"name": "Joseph P. Hagan", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}